CBUS
Cibus, Inc.
CBUS offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over CBUS overall, supported by lower modeled downside and stronger valuation.
CBUS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
CBUS's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CBUS PE Valuation
CBUS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CBUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect CBUS's revenue to grow, with its earnings and profitability holding steady.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CBUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.30 | +$2.03 |
| Q2 2026 | -$1.45 | +$9.07 |
| Q1 2026 | -$1.77 | +$9.28 |
| Q4 2025 | -$2.78 | +$8.05 |
| Q3 2025 | -$3.33 | +$26.78 |
| Q2 2025 | -$10.52 | +$13.55 |
| Q1 2025 | -$11.05 | +$14.93 |
| Q4 2024 | -$10.83 | +$19.48 |
CBUS is still losing money, but far less than before: $1.30 per share over the past year, against $68.00 at its worst in mid-2020.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CBUS on earnings quality, reporting a profit while its opponent remains loss making.
CBUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $800K | +30% |
| Q2 2026 | $994K | +6.5% |
| Q1 2026 | $1.7M | +63% |
| Q4 2025 | $1.1M | -13% |
| Q3 2025 | $615K | -63% |
| Q2 2025 | $933K | +11% |
| Q1 2025 | $1M | +90% |
| Q4 2024 | $1.2M | +9.9% |
CBUS's revenue is recovering but still below its 2020 peak: $800,000 last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1563% | +947 points |
| Q2 2026 | -1300% | +623 points |
| Q1 2026 | -721% | +3299 points |
| Q4 2025 | -2136% | -649 points |
| Q3 2025 | -2510% | +9514 points |
| Q2 2025 | -1923% | +640 points |
| Q1 2025 | -4020% | -635 points |
| Q4 2024 | -1487% | +22929 points |
CBUS's operating margin was −1563% last quarter, up 947 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CBUS on profitability, with a higher operating margin.
CBUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.3M | +$2.5M |
| Q2 2026 | -$9.4M | +$4.3M |
| Q1 2026 | -$11.6M | +$517K |
| Q4 2025 | -$13.5M | +$545K |
| Q3 2025 | -$11.8M | +$2M |
| Q2 2025 | -$13.7M | +$3.5M |
| Q1 2025 | -$12.1M | +$1.6M |
| Q4 2024 | -$14.1M | +$3.4M |
CBUS has burned cash in almost every quarter: −$44M over the past year, against −$52M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CBUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
CBUS Net Leverage
CBUS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CBUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 4.7 | Oversold |
CBUS's weekly RSI is 38 (neutral) and its Stochastic is 5 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CBUS PE vs Healthcare Sector
CBUS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CBUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.38 | 21% below |
| 20 week MA | $1.58 | 31% below |
| 50 week MA | $1.77 | 38% below |
| 100 week MA | $1.82 | 40% below |
| 200 week MA | $8.07 | 86% below |
CBUS is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CBUS on trend strength, trading above more of its moving averages.
CBUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $320.5 | $215.5 | -33% |
| 2021 | $215.5 | $111.5 | -48% |
| 2022 | $111.5 | $6.60 | -94% |
| 2023 | $6.60 | $19.6 | +198% |
| 2024 | $19.6 | $2.36 | -88% |
| 2025 | $2.36 | $1.70 | -28% |
| 2026 YTD | $1.70 | $1.09 | -36% |
CBUS's yearly returns have swung widely, from +198% in 2023 to −94% in 2022. It's down 36% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over CBUS on returns for 2026, with the stronger performance.